LY2857785LY2857785 is a potent and selective CDK9 inhibitor; significantly reduces RNAP II CTD phosphorylation and dramatically decreases MCL1 protein levels to result in apoptosis in a variety of leukemia and solid tumor cell lines.
IC50 value:
Target: CDK9 inhibitor
LY2857785 inhibits the growth of a broad panel of cancer cell lines, and is particularly efficacious in leukemia cells, including orthotopic leukemia preclinical models as well as in ex vivo acute myeloid leukemia and chronic lymphocytic leukemia patient tumor samples.
MedChemexpress(MCE)provides a wide range of research chemicals and biochemicals including novel life-science reagents, reference compounds, APIs and Natural compounds for laboratory and scientific use. MCE has an enthusiastic, energetic and friendly Technical and Customer Support team with years of experience in the Life Science industry. MCE lay great attention on the purity, stability and activity of the compounds, esp. You can rely on us to be a com...
View more >>
Description: LY2835219 LY2835219 is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM, respectively. IC50 Value: 2 nM(CDK4); 10 nM(CDK6) Target: CDK4/6 in vitro: LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor ...
Description: LY2157299 LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. IC50 value: 56 nM [1] Target: TGFβ receptor I in vitro: LY2157299 potently inhibits the TGFβ receptor signaling. Target: NMDA Receptor Product Links: http://www....